

ANTIPARASITIC AGENTS AND
PROCESS FOR THEIR PREPARATION

Cross-Reference to Related Application

This application is a continuation-in-part of
application Serial No. 886,867, filed July 16, 1986, now abandoned.

Background of the Invention

Field of the Invention

This invention relates to antiparasitic agents and
in particular to compounds related to the avermectins
and milbemycins but having a novel substituent group at
the 25-position and to a process for their preparation.

Description of the Prior Art

The avermectins are a group of broad spectrum
antiparasitic agents referred to previously as the
C-076 compounds. They are produced by fermenting a
strain of the microorganism Streptomyces avermitilis
ATCC 31267, 31271 or 31272 under aerobic conditions in
an aqueous nutrient medium containing inorganic salts
and assimilable sources of carbon and nitrogen. The
morphological and cultural properties of the strains
ATCC 31267, 31271 and 31272 are described in detail in
British Patent Specification No. 1573955 which also
describes the isolation and the chemical structure of
the eight individual components which make up the C-076
complex. The milbemycins are structurally related
macrolide antibiotics lacking the sugar residues at the
13-position. They are produced by fermentation, for
example as described in British Patent Specification
No. 1390336 and European Patent Application Publication
No. 0170006.


Summary of the Invention

We have now discovered that by adding certain
specified carboxylic acids, or derivatives thereof, to
the fermentation of an avermectin producing organism it
is possible to obtain novel compounds, related to the

avermectins but having an unnatural substituent group at the 25-position in place of the isopropyl or sec-butyl group which is normally present. The novel compounds are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasitocides, insecticides and acaricides.

Thus, according to one aspect of the invention there is provided a process for producing a novel avermectin derivative having an unnatural substituent group at the 25-position which comprises adding a carboxylic acid, or a salt, ester or amide thereof or oxidative precursor therefor, to a fermentation of an avermectin producing organism, and isolating the novel avermectin derivative.

Conventional chemical transformation reactions can be used to prepare further derivatives from these compounds. Thus, according to a further aspect of the invention there are provided compounds having the formula:



P₃ H
L

wherein R when taken individually is H; R¹ when taken individually is H or OH; R and R¹ when taken together represent a double bond;

P₁ H 14
L L 5

R² is an alpha-branched C₃-C₈ alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group; a C₅-C₈ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C₂-C₅ alkyl group; a C₃-C₈ cycloalkyl or C₅-C₈ cycloalkenyl group, either of which may be substituted by methylene or one or more C₁-C₄ alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may be substituted by one or more C₁-C₄ alkyl groups or halo atoms;

H 14
L L


10

H 14
L

P₁ H 15
L L 40

R³ is hydrogen or methyl;

R⁴ is H or a 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group of the formula:



TSOX

P₃ H
L 20

with the proviso that when R² is alkyl it is not isopropyl or sec-butyl; when R⁴ is H, each of R and R¹ is H, and R² is not methyl or ethyl; and when R⁴ is H, R is H, R¹ is OH, and R² is not 2-buten-2-yl, 2-penten-2-yl or 4-methyl-2-penten-2-yl.

P

25

In the above definition, alkyl groups containing 3 or more carbon atoms may be straight or branched chain. Halo means fluoro, chloro, bromo or iodo. Alpha-branched means that the carbon atom attached to the 25-ring position is a secondary carbon atom linked to two

further carbon atoms. When R^2 is alkyl of 5 or more carbon atoms, the remainder of the alkyl chain may be straight or branched chain.

Preferred compounds of the formula I are those wherein R^4 is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy. Also preferred are compounds of the formula I wherein R^2 is a C_5 or C_6 cycloalkyl or cycloalkenyl group which may be substituted by one or more C_1 - C_4 alkyl groups, cyclopentyl and cyclohexyl being particularly preferred. In another group of preferred compounds R^2 is cyclobutyl. In a further group of preferred compounds R^2 is a 5 or 6 membered oxygen or sulphur containing heterocyclic ring, particularly a 3-thienyl or 3-furyl ring, which may be substituted by one or more C_1 - C_4 alkyl groups or halogen atoms. In a yet further group of preferred compounds, R^2 is a C_3 - C_8 alkylthioalkyl group, particularly a 1-methylthioethyl group.

Detailed Description of the Invention

In accordance with the invention the compounds of formula I wherein R is H and R^1 is OH or wherein R and R^1 taken together represent a double bond, and R^4 is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy are prepared by fermenting an avermectin producing organism, such as a strain of the organism Streptomyces avermitilis ATCC 31267, 31271 or 31272, in the presence of the appropriate carboxylic acid of the formula R^2CO_2H , wherein R^2 is as previously defined, or a salt, ester, or amide thereof or oxidative precursor therefor. The acid is added to the fermentation either at the time of inoculation or at intervals during the fermentation. Production of the compounds of formula (I) may be monitored by removing samples from the fermentation, extracting with an organic solvent and following the

appearance of the compound of formula (I) by chromatography, for example using high pressure liquid chromatography. Incubation is continued until the yield of the compound of formula (I) has been maximised, generally
5 for a period of from 4 to 6 days.

A preferred level of each addition of the carboxylic acid or derivative thereof is between 0.05 and 1.0 grams per litre. The best yields of the compounds of formula (I) are obtained by gradually adding the acid
10 to the fermentation, for example by daily additions of the acid or derivative thereof over a period of several days. The acid is preferably added as a salt, such as the sodium or ammonium salt, but may be added as an ester, such as the methyl or ethyl ester or as an amide.

15 Alternative substrates which may be used in the fermentation are derivatives which are oxidative precursors for the carboxylic acids; thus, for example suitable substrates would be aminoacids of the formula $R^2CH(NH_2)CO_2H$, glyoxylic acids of the formula R^2COCO_2H , methylamine
20 derivatives of the formula $R^2CH_2NH_2$, substituted lower alkanolic acids of the formula $R^2(CH_2)_nCO_2H$ wherein n is 2, 4 or 6, methanol derivatives of the formula R^2CH_2OH or aldehydes of the formula R^2CHO , wherein R^2 is as previously defined. The media used for the fermentation
25 may be a conventional complex media containing assimilable sources of carbon, nitrogen and other trace elements.

However we have found that for better results a strain
I of the organism derived from Streptomyces avermitilis ATCC 31271 which gives improved yields of a compound of
30 formula I when cultured in a semi-defined medium may be used and this has the advantage that crude solvent extracts contain significantly less unwanted material which greatly simplifies the subsequent isolation and purification stages. Such a strain has been deposited

with the National Collection of Industrial Bacteria (NCIB) on 19th July, 1985 under the accession number NCIB 12121. The morphological and cultural characteristics of this strain are otherwise generally as described in British Patent specification No. 1573955 for strain ATCC 31267.

After fermentation for a period of several days at a temperature preferably in the range of from 24° to 33° C., the fermentation broth is centrifuged or filtered and the mycelial cake is extracted with acetone or methanol. The solvent extract is concentrated and the desired product is then extracted into a water-immiscible organic solvent, such as methylene chloride, ethyl acetate, chloroform, butanol or methyl isobutyl ketone. The solvent extract is concentrated and the crude product containing the compounds of formula (I) is further purified as necessary by chromatography, for example using preparative reverse phase, high pressure liquid chromatography.

20 The product is generally obtained as a mixture of the compounds of formula (I) wherein R^4 is 4'-(α -L-oleandrosyl)- α -L-oleandrosyloxy, R is H, R^1 is OH or R and R^1 taken together represent a double bond and wherein R^3 is H or CH_3 ; however the proportions can vary depending on the particular carboxylic acid employed and the conditions used.

25 We have found that a broad range of carboxylic acids as defined by R^2CO_2H may be added to the fermentation to yield avermectins having a novel substituent group at the 25-position. Examples of particular acids which may be employed include the following:

- 2-methylvaleric acid
- 2-methylpent-4-enoic acid
- 2-methylthiopropionic acid
- 35 2-cyclopropyl propionic acid

P,
|
P
5 cyclobutane carboxylic acid
cyclopentane carboxylic acid
cyclohexane carboxylic acid
cycloheptane carboxylic acid
2-methylcyclopropane carboxylic acid
3-cyclohexene-1-carboxylic acid
and thiophene-3-carboxylic acid

40 A
10 In one particular and preferred aspect of the invention, the fermentation is performed in the presence of cyclopentane carboxylic acid sodium salt to yield predominantly the compound of formula (I) wherein R is H, R¹ is OH, R² is cyclopentyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy.

15 In another preferred aspect of the invention, the fermentation is performed in the presence of thiophene-3-carboxylic acid sodium salt to yield predominantly the compound of (I) where R is H, R¹ is OH, R² is thien-3-yl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy.

20 In a further preferred aspect of the invention the fermentation is performed in the presence of 2-methylthiopropionic acid sodium salt to yield predominantly the compound of formula (I) wherein R is H, R¹ is OH, R² is 1-methylthioethyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy.
25

H
L
H
4
30 Compounds of the formula (I) wherein the C₂₂₋₂₃ double bond is present may alternatively be prepared from the corresponding compound of formula (I) wherein R is H and R¹ is OH by a dehydration reaction. The reaction is performed by first selectively protecting the hydroxyl groups at the 5 and 4" positions, e.g. as the t-butyldimethylsilyloxy acetyl derivative, then reacting with a substituted thiocarbonyl halide, such as (4-methylphenoxy)thiocarbonyl chloride, followed by

heating in a high boiling point solvent, e.g. trichloro-
benzene, to effect the dehydration. The product is
finally deprotected to give the unsaturated compound.
These steps together with appropriate reagents and
F 5 reaction conditions are described in United States
patent 4,328,335.

H The compounds of formula I wherein R^3 is H may
also be prepared from the corresponding compounds
H wherein R^3 is CH_3 by demethylation. This reaction is
10 achieved by treating the 5-methoxy compound, or a
suitably protected derivative thereof, with mercuric
acetate and hydrolysing the resulting 3-acetoxy enol
ether with dilute acid to give the 5-keto compound.
This is then reduced using, for example, sodium boro-
15 hydride to yield the 5-hydroxy derivative. Appropriate
reagents and reaction conditions for these steps are
described in United States patent 4,423,209.

F
H The compounds of formula I wherein each of R and
H14 20 R^1 is H can be prepared from the corresponding compound
wherein the double bond is present at $C_{22}-C_{23}$ by selec-
tive catalytic hydrogenation using an appropriate
catalyst. For example the reduction may be achieved
using tris(triphenylphosphine)rhodium (I) chloride as
described in European patent application publication
25 No. 0001689.

H The compounds of formula (I) wherein R^4 is H are
L prepared from the corresponding compounds wherein R^4 is
40 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy by
L removing the 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrose
30 group by mild hydrolysis with an acid in an aqueous
organic solvent to yield the aglycone having a hydroxy
group at the 13-position; this is then halogenated, for
example by reaction with a benzene sulphonyl halide, to
yield the 13-deoxy-13-halo derivative which is finally

selectively reduced, for example using tributyltin hydride. In order to avoid unwanted side reactions it is desirable to protect any other hydroxy groups which may be present, for example using a tert-butyldimethylsilyl group. This is then readily removed after the halogenation or reduction step by treatment with methanol containing a trace of acid. All these steps together with appropriate reagents and reaction conditions for their performance are described in European patent application publication No. 0002615.

Compounds of the formula (I) wherein each of R and R⁴ is H and R¹ is either H or OH, may also be prepared by adding the appropriate carboxylic acid, or a salt, ester or amide thereof or oxidative precursor therefor, to a fermentation of a milbemycin producing organism, and isolating the desired milbemycin derivative having an unnatural substituent group at the 25-position. Examples of milbemycin producing organisms include for instance Streptomyces hygroscopicus strain NRRL 5739 as described in British Patent Specification No. 1390336, Streptomyces cyaneogriseus subsp. noncyanogenus NRRL 15773 as described in European patent application publication No. 0170006 and Streptomyces thermoarchaenis NCIB 12015 as described in GB 2166436A.

The compounds of the invention are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasitocides, insecticides and acaricides.

Thus the compounds are effective in treating ^{and preventing} a variety of conditions caused by endoparasites including, in particular, helminthiasis which is most frequently caused by a group of parasitic worms described as nematodes and which can cause severe economic losses in swine, sheep, horses and cattle as well as affecting

domestic animals and poultry. The compounds are also effective against other nematodes which affect various species of animals including, for example, Dirofilaria in dogs and various parasites such as Ancylostoma,
5 Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, Enterobius and parasites which are found in the blood or other tissues and organs such as filarial worms and the extra intestinal stages of Strongyloides and Trichinella.

a 10 The compounds are also of value in treating ^{and preventing} ecto-parasite infections including in particular arthropod ectoparasites of animals and birds such as ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae which can affect cattle and horses.

15 The compounds are also insecticides active against household pests such as the cockroach, clothes moth, carpet beetle and the housefly as well as being useful against insect pests of stored grain and of agricultural plants such as spider mites, aphids, caterpillars and
20 against migratory orthopterans such as locusts.

The compounds of formula (I) are administered as a formulation appropriate to the specific use envisaged and to the particular species of host animal being treated and the parasite or insect involved. For use
25 as an anthelmintic the compounds may be administered orally in the form of a capsule, bolus, tablet or preferably a liquid drench, or alternatively, they may be administered by injection or as an implant. Such formulations are prepared in a conventional manner in
30 accordance with standard veterinary practice. Thus, capsules, boluses or tablets may be prepared by mixing the active ingredient with a suitable finely divided diluent or carrier additionally containing a disintegrating agent and/or binder such as starch, lactose, talc,

magnesium stearate, etc. A drench formulation may be prepared by dispersing the active ingredient in an aqueous solution together with dispersing or wetting agents etc. and injectable formulations may be prepared
5 in the form of a sterile solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. These formulations will vary with regard to the weight of active compound depending on the species of host animal
10 to be treated, the severity and type of infection and the body weight of the host. Generally for oral administration a dose of from about 0.001 to 10 mg per Kg of animal body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but of course there can be instances where higher
15 or lower dosage ranges are indicated and such are within the scope of this invention.

As an alternative the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for
20 mixing with the normal animal feed.

For use as an insecticide and for treating agricultural pests the compounds are applied as sprays, dusts, emulsions and the like in accordance with standard
25 agricultural practice.

The invention is illustrated by the following Examples in which Examples 1 to 21 are Examples of the preparation of compounds of the formula (I), Example 22 is an example of a drench formulation and Examples 23
30 and 24 illustrate the antiparasitic and insecticidal activity of the compounds.

chromatograph using the same solvent at a flow rate of 100 ml per minute. Fractions 35 to 50 containing the desired product were combined and rechromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (4:1) at a flow rate of 9 ml per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R is H, R¹ is OH, R² is cyclopentyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy as a white powder, m.p. 150.5-151° C. The structure of the product was confirmed by mass spectrometry and by C13 nuclear magnetic resonance spectroscopy as follows:

Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 939 (theoretical 939).

Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 335, 317, 275, 257, 251, 233, 205, 181, 179, 145, 127, 113, 111, 95 and 87.

The 13C nuclear magnetic resonance spectral data were obtained on a Bruker Model WM-250 spectrometer with a sample concentration of 20 mg/ml in deuteriochloroform. The chemical shifts in parts per million relative to tetramethylsilane were: 14.1, 15.3, 17.8, 18.5, 19.9, 20.3, 24.6, 25.9, 26.2, 29.3, 34.4 (2C), 34.7, 36.7, 37.8, 39.8, 40.5, 41.0, 41.3, 45.8, 56.4, 56.6, 57.8, 67.4, 67.6, 68.0, 68.3, 68.7, 69.9, 70.5, 76.0, 77.6 (2C), 78.3, 79.5, 80.7 (2C), 81.8, 94.9, 98.7, 99.8, 117.7, 118.5, 119.8, 125.0, 135.8, 136.3, 137.8, 140.1 and 173.8.

CL
L
PT

EXAMPLE 1

25-Cyclopentyl-avermectin A2

A suspension of a slope culture of S. avermitilis NCIB 12121 was inoculated into 600 ml of a medium containing lactose (12.0 g), distillers solubles (8.0 g) and yeast extract (3.0 g), contained in a 3 litre flask, and incubated at 28° C. for 3 days. The inoculum was used to inoculate 16 litres of a medium containing soluble starch (640 g), ammonium sulphate (32 g), dipotassium hydrogen phosphate (16 g), sodium chloride (16 g), magnesium sulphate 7H₂O (16 g), calcium carbonate (32 g), soluble yeast extract (6.4 g), ferrous sulphate 7H₂O (0.016 g), zinc sulphate 7H₂O (0.016 g) and manganese chloride 4H₂O (0.016 g), contained in a 20 litre fermenter. The fermentation was incubated at 28° C., with agitation at 250 r.p.m. and aerated at 15 litres per minute. Cyclopentane carboxylic acid sodium salt (1.6 g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium was removed by filtration and extracted with acetone: 1N-hydrochloric acid (100:1; 3 x 7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2 x 5 litres). The methylene chloride extract was concentrated to dryness to give the crude product as a mobile oil which was dissolved in diethyl ether and added to a column of silica gel (1 kg). The column was eluted with diethyl ether collecting 100 ml fractions. Fractions 20-40 were combined and the solvent evaporated to yield partially purified material. The product was dissolved in a mixture of methanol and water (4:1) and chromatographed on a C18 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid

33

CL
PI

EXAMPLE 2

A suspension of a slope culture of S. avermitilis ATCC 31271 was inoculated into 50 ml of a medium containing lactose (1.0 g), distillers solubles (0.75 g) and yeast extract (0.25 g), contained in a 350 ml flask, and incubated at 28° C. for 3 days. This inoculum (4 ml) was used to inoculate each of 50 flasks containing 50 ml of medium containing corn starch (2.0 g), soya flour (0.35 g) and yeast extract (0.25 g) contained in a 350 ml flask, and the flasks were incubated at 28° C.

After 24 hours, cyclopentane carboxylic acid sodium salt (5 mg) was added to each flask and incubation was continued for a further 5 days. After this time the contents of the flasks were bulked and the mycelium separated by centrifugation. The mycelium was extracted with acetone:1N-hydrochloric acid (100:1) and the acetone extract concentrated to dryness. The extract was analysed by high pressure liquid chromatography and was shown to contain a product identical with the product of Example 1.

CL
P

EXAMPLE 3

An inoculum was prepared as described in Example 1 and used to inoculate 50 ml of the medium as used in Example 1, contained in 350 ml flasks. After incubation for 24 hours, 2-aminocyclopentyl acetic acid (cyclopentylglycine) (5 mg) was added and the fermentation was continued for a further 5 days. The product was recovered by extraction of the mycelium with acetone and methylene chloride. The extract was analyzed by HPLC which indicated that the product contained a compound identical to the product of Example 1.

CL
P

EXAMPLE 4

The conditions of Example 3 were followed except that cyclopentyl methanol was used as substrate with similar results.

CL 5
P

EXAMPLE 5

The conditions of Example 3 were followed except that the methyl ester of cyclopentane carboxylic acid, dissolved in methanol, was used as substrate with similar results.

CL 10
P

EXAMPLE 6

The conditions of Example 3 were followed except that cyclopentane carboxylic acid, dissolved in methanol was used as substrate with similar results.

CL
L 15
P I

EXAMPLE 7

25-(Thien-3-yl) avermectin

A suspension of a slope culture of S. avermitilis NCIB 12121 was inoculated into 600 ml of a medium containing lactose (12.0 g), distillers solubles (8.0 g) and yeast extract (3.0 g), contained in a 3
20 litre flask, and incubated at 28° C. for 3 days. The inoculum was used to inoculate 16 litres of a medium containing soluble starch (640 g), ammonium sulphate (32 g), dipotassium hydrogen phosphate (16 g), sodium
H chloride (16 g), magnesium sulphate 7H₂O (16 g), calcium
25 carbonate (32 g), soluble yeast extract (6.4 g), ferrous
H sulphate 7H₂O (0.016 g), zinc sulphate 7H₂O (0.016 g)
L and manganese chloride 4H₂O (0.016 g), contained in a 20 litre fermenter. The fermentation was incubated at
28° C., with agitation at 250 r.p.m. and aerated at 15
30 litres per minute. Thiophene-3-carboxylic acid sodium salt (1.6 g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium

33 was removed by filtration and extracted with acetone:1N-
hydrochloric acid (100:1; 3 x 7 litres). The extract
was concentrated to approximately 2 litres under reduced
pressure and extracted with methylene chloride (2 x 5
5 litres). The methylene chloride extract was concen-
trated to dryness to give the crude product as a mobile
oil which was dissolved in diethyl ether and added to a
column of silica gel (1 kg). The column was eluted
with diethyl ether collecting 200 ml fractions. Frac-
14 10 tions 32-45 were combined and the solvent evaporated to
yield partially purified material. The product was
dissolved in a mixture of methanol and water (3:1) and
chromatographed on a C18 Micro-Bondapack column (50 mm
33 x 50 cm) in a Waters Prep 500 high pressure liquid
15 chromatograph using the same solvent at a flow rate of
100 ml per minute. Fractions 27 to 36 containing the
desired product were combined and rechromatographed on
33 a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x
25 cm) eluting with a mixture of methanol and water
20 (3:1) at a flow rate of 9 ml per minute. The relevant
fractions were combined and the solvent evaporated to
H 40 yield the compound of formula (I) wherein R is H, R¹ is
OH, R² is thien-3-yl, R³ is CH₃ and R⁴ is 4'-(alpha-L-
oleandrosyl)-alpha-L-oleandrosyloxy as a white powder,
25 m.p. 167° C. The structure of the product was confirmed
by mass spectrometry as follows:

Fast atom bombardment mass spectrometry was per-
formed on a VG Model 7070E mass spectrometer using a
sample matrix of triethylene glycol with solid sodium
H 30 chloride. (M + Na)⁺ observed at m/e 953 (theoretical
953).

Electron impact mass spectrometry was performed
using a VG Model 7070F mass spectrometer. The m/e

values for the principal fragments were: 349, 331, 275, 265, 257, 247, 237, 219, 195, 145, 127, 113, 95 and 87.

EXAMPLE 8

CL
PI 5 A vegetative cell suspension of S. avermitilis
31 NCIB 12121, held at -60° C. in 10% v/v aqueous (2 ml) glycerol was inoculated into 50 ml of medium containing lactose (1.0 g), distillers solubles (0.75 g) and yeast extract (0.25 g) contained in a 300 ml conical flask
10 and incubated at 28° C. for 24 hours, with shaking. The inoculum was then added to 600 ml of the above medium contained in a 3 litre flask and the mixture was incubated at 28° C. for 24 hours with shaking. The product was used to inoculate 10 litres of the above
15 medium contained in a 16 litre fermenter which was incubated at 28° C. for 24 hours at an agitation speed of 350 r.p.m. with aeration at 10 litres of air per minute. This fermentation (600 ml) was used to inoculate 16 litres of a medium containing partially
20 hydrolysed starch (640 g) ammonium sulphate (32 g), dipotassium hydrogen phosphate (16 g), sodium chloride
H (16 g) magnesium sulphate 7H₂O (16 g), calcium carbonate
H (32 g), soluble yeast extract (6.4 g), ferrous sulphate
L 7H₂O (0.016 g), zinc sulphate 7H₂O (0.016 g), and man-
25 ganese chloride 4H₂O (0.016 g), contained in a 20 litre fermenter. The fermentation was incubated at 28° C., with agitation at 350 r.p.m. and aerated at 15 litres per minute. Cyclobutane carboxylic acid sodium salt
30 (1.6 g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium was removed
33 by filtration and extracted with acetone (3 x 7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene

33 chloride (2 x 5 litres). The methylene chloride was concentrated to dryness to give the crude product as a mobile oil. This was taken up in iso-octane (150 ml) and the solution extracted with a mixture of methanol (95 ml) and water (5 ml). Evaporation of the methanolic extract gave partially purified material which was separated into its individual components by high pressure liquid chromatography as follows: The residue was dissolved in a little methanol and chromatographed in a C18 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using a mixture of methanol/water (4:1) at a flow rate of 100 ml per minute. Fractions 1 to 4 were combined and used in Example 9, fractions 5 to 9 were combined and used in Example 10, fractions 10 to 19 were combined and used in Example 11 and fractions 20 to 35 were combined and used in Example 12.

EXAMPLE 9

25-Cyclobutyl-avermectin B2 ($R^1 = OH$, R and $R^3 = H$)

The combined fractions 1 to 4 from Example 8 were evaporated to dryness and the residue was rechromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (3:1) at a flow rate of 9 ml per minute. The relevant fractions were combined, the solvent evaporated and the product subjected to a final purification on a Silica Spherisorb 5 micron (Trademark, HPLC Technology) column (10.5 mm x 25 cm) eluting with a mixture of methylene chloride and methanol (98:2) at a flow rate of 4 ml per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R is H, R^1 is OH, R^2 is cyclobutyl, R^3 is H and R^4 is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy, as a white powder, m.p. 110-112° C.

The structure of the product was confirmed by mass spectrometry as follows:

Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 911 (theoretical 911).

Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 321, 303, 261, 257, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.

EXAMPLE 10

25-Cyclobutyl-avermectin A2 (R¹ = OH, R = H, R³ = CH₃)

The combined fractions 5 to 9 from Example 8 were evaporated to dryness and the residue was rechromatographed twice on a C18 Zorbax ODS (Trademark, Dupont) column, (21 mm x 25 cm) eluting with a methanol and water mixture (77:23) at a flow rate of 9 ml per minute. Suitable fractions were combined and evaporated to yield the compound of formula (I) wherein R is H, R¹ is OH, R² is cyclobutyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy, as a white powder, m.p. 135-140° C.

The structure of the product was confirmed by mass spectrometry as follows:

Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 925 (theoretical 925).

Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 596, 454,

CL
LH
P

33

H
L40

14

25

H 30

321, 303, 275, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.

EXAMPLE 11

25-Cyclobutyl-avermectin B1

5 (R and R¹ taken together = Double bond, R³ = H)

The combined fractions 10 to 19 from Example 8 were evaporated to dryness and the residue dissolved in methanol and chromatographed on a C18 Zorbax ODS

33 (Trademark, Dupont) column, (21 mm x 25 cm) eluting with a mixture of methanol and water (4:1) at a flow rate of 9 ml per minute. The relevant fractions were combined and the solvent evaporated to give a product

33 10 which was rechromatographed on a Silica Zorbax SIL (Trademark, Dupont) column (21 mm x 25 cm) eluting with 15 a mixture of dichloromethane and methanol (98.5:1.5) at a flow rate of 9 ml per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R and R¹ taken together represent a double bond, R² is cyclobutyl, R³ is H and R⁴ is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy, as a 14 white powder, m.p. 135-138° C.

The structure of the product was confirmed by mass spectrometry as follows:

25 Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 893 (theoretical 893).

4 30 Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 303, 261, 257, 219, 191, 167, 145, 127, 113, 111, 95 and 87.

EXAMPLE 12

25-Cyclobutyl-avermectin A1

(R and R¹ taken together = Double bond, R³ = CH₃)

The combined fractions 20 to 35 from Example 8 were evaporated to dryness and the residue chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) at a flow rate of 9 ml per minute. The relevant fractions were combined, the solvent evaporated and the product was rechromatographed on a Silica Sperisorb 5 micron (Trademark, HPLC Technology) column (10.5 mm x 25 cm) eluting with a mixture of dichloromethane and methanol (98.5:1.5) at a flow rate of 4 ml per minute. Combination of the relevant fractions followed by evaporation gave the compound of formula (I) wherein R and R¹ taken together represent a double bond, R² is cyclobutyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy, as a white powder, m.p. 120-124° C.

The structure of the product was confirmed by mass spectrometry as follows:

Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 907 (theoretical 907).

Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 578, 303, 275, 257, 219, 191, 167, 145, 127, 113, 111, 95 and 87.

EXAMPLE 13

25-(Cyclohex-3-enyl) avermectin A2

The medium and conditions of Example 1 were followed except that 3-cyclohexenoic acid sodium salt was used as the substrate to yield the compound of formula I wherein R is H, R¹ is OH, R² is cyclohex-3-enyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy, as a white powder, m.p. 131-5° C.

The structure of the product was confirmed by mass spectrometry as follows:

Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 951 (theoretical 951).

Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 624, 480, 347, 329, 275, 245, 235, 217, 205, 193, 179, 145, 127, 113, 111, 95 and 87.

EXAMPLE 14

25-Cyclohexyl avermectin A2

The medium and conditions of Example 1 were followed except that cyclohexane carboxylic acid sodium salt was used as the substrate to yield the compound of formula I wherein R is H, R¹ is OH, R² is cyclohexyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy, as a white powder, m.p. 112-117° C.

The structure of the product was confirmed by mass spectrometry as follows:

Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 953 (theoretical 953).

Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 624, 482, 349, 331, 275, 265, 247, 237, 219, 207, 195, 179, 145, 127, 113, 111, 95 and 87.

EXAMPLE 15

25-(1-Methylthioethyl) avermectin A2

The medium and conditions of Example 1 were followed except that 2-methylthiopropionic acid sodium salt was used as the substrate to yield the compound of formula I wherein R is H, R¹ is OH, R² is 1-methylthioethyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy, as a white powder, m.p. 134-138° C.

The structure of the product was confirmed by mass spectrometry as follows:

Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 945 (theoretical 945).

Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 341, 323, 275, 263, 257, 239, 211, 187, 179, 145, 127, 113, 111, 95 and 87.

EXAMPLE 16

25-(2-Methylcyclopropyl) avermectin A2

The medium and conditions of Example 1 were followed except that 2-methylcyclopropane carboxylic acid sodium salt was used as the substrate to yield the compound of formula I wherein R is H, R¹ is OH, R² is 2-methylcyclopropyl, R³ is CH₃ and R⁴ is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy, as a white powder, m.p. 147-150° C.

The structure of the product was confirmed by mass spectrometry as follows:

Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)⁺ observed at m/e 925 (theoretical 925).

Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 596, 454, 303, 275, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.

EXAMPLE 17

The procedure of Example 1 was followed but using the sodium salt of the following carboxylic acids as substrate instead of cyclopentane carboxylic acid to yield the appropriate 25-substituted avermectins of formula (I) wherein R is H, R¹ is OH, or R and R¹ taken together represent a double bond, R³ is H or OH and R⁴ is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy:

2-methylvaleric acid
2,3-dimethylbutyric acid
2-methylhexanoic acid
2-methylpent-4-enoic acid
2-cyclopropyl propionic acid
cycloheptane carboxylic acid
4,4-difluorocyclohexane carboxylic acid
4-methylenecyclohexane carboxylic acid
3-methylcyclohexane carboxylic acid
cyclopentene-1-carboxylic acid
1-cyclohexene carboxylic acid
tetrahydropyran-4-carboxylic acid
3-furoic acid
and 2-chloro-thiophene-4-carboxylic acid.

CC
P

H
L
40
P

EXAMPLE 18

Repetition of the procedure of Example 17 but using the carboxylic acids (as their sodium salts) enumerated below, the appropriate 25-substituted
5 avermectins characterized in Table I were obtained:

- 6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
- cyclohexane carboxylic acid
 - cyclohex-3-ene carboxylic acid
 - cyclopentane carboxylic acid
 - 2-methylpent-3-enoic acid
 - 2-methylpropionic acid
 - thiophene-3-carboxylic acid
 - exomethylenecyclohexane carboxylic acid
 - furan-3-carboxylic acid
 - 2-methylvaleric acid
 - thiophene-2-carboxylic acid
 - tetrahydropyran-4-carboxylic acid
 - 2-methyl-4-methoxybutyric acid
 - 2-methylpent-3-ynoic acid
 - cyclopent-3-ene carboxylic acid
 - 3,4-dihydropyran-2-carboxylic acid.

Table 1

Physical and Spectroscopic Data for Novel C-25 Avermectins

25 Substituent (R ²)	Sub-class	m.p. °C.	Theoretical Mol. Wt.	(M+Na) ⁺ From FAB Mass Spec.	m/e for Principle Fragments in the EI Mass. Spec.
Cyclohexyl	A1	110-115	912	935	606, 331, 275, 257, 247, 218, 195, 145, 127, 113, 95 and 87.
	B1	116-9	898	921	592, 331, 257, 247, 219, 195, 145, 127, 113, 95 and 87.
	B2	146-8	916	939	610, 482, 349, 331, 275, 265, 257, 179, 145, 127, 113, 95 and 87.
3-Cyclohexenyl	H ₂ B1*	150 (dec)	900	923	594, 333, 249, 221, 145, 127, 113, 95 and 87.
	B1	122-129	896	919	590, 329, 257, 245, 217, 193, 145, 127, 113, 95 and 87.

T280K

25 Substituent (R ²)	Sub-class	m.p. °C.	Theoretical Mol. Wt.	(M+Na) ⁺ From FAB Mass Spec.	m/e for Principle Fragments in the EI Mass. Spec.
Cyclopentyl	B1	158-162	884	907	578, 468, 317, 257, 233, 205, 145, 127, 113, 95 and 87.
	B2	158-164	902	925	596, 468, 335, 317, 257, 251, 233, 179, 145, 127, 113, 95 and 87.
	H ₂ B1*	145-147	886	909	580, 319, 257, 207, 145, 127, 113, 95 and 87.
1-Methylbut-3-enyl	A2	149-151	916	939	610, 335, 317, 275, 251, 233, 223, 205, 179, 145, 127, 113, 95 and 87.
	B1	141-144	884	907	596, 578, 317, 261, 257, 233, 205, 145, 127, 113, 95 and 87.
1-Methylthioethyl	B1	144-147	890	913	584, 323, 261, 257, 239, 211, 187, 145, 127, 113, 95 and 87.

<u>25 Substituent (R²)</u>	<u>Sub- class</u>	<u>m.p. °C.</u>	<u>Theoretical Mol. Wt.</u>	<u>(M+Na)⁺ From FAB Mass Spec.</u>	<u>m/e for Principle Fragments in the EI Mass. Spec.</u>
3-Thienyl	B1	155-165	898	921	610, 592, 574, 482, 331, 261, 257, 247, 219, 195, 145, 127, 113, 95 and 87.
	B2	175-180	916	939	610, 331, 257, 249, 234, 219, 179, 145, 127, 113, 95 and 87.
Exomethylene- cyclohexyl	B1	161-165	910	933	604, 343, 261, 259, 231, 207, 145, 127, 113, 95 and 87.
3-Furanyl	A2	148-153	914	937	333, 315, 275, 257, 249, 231, 221, 203, 179, 145, 127, 113, 95 and 87.
	B1	145-150	882	905	576, 315, 261, 257, 231, 203, 179, 145, 127, 113, 95 and 87.

25 Substituent (R ²)	Sub-class	m.p. °C.	Theoretical Mol. Wt.	(M+Na) ⁺ From FAB Mass Spec.	m/e for Principle Fragments in the EI Mass. Spec.
1-Methylbutyl	A1	---	900	923	594, 470, 319, 275, 257, 207, 183, 145, 127, 113, 95 and 87.
	B1	148-150	886	909	580, 337, 319, 261, 257, 253, 225, 207, 183, 145, 127, 113, 111, 95 and 87.
2-Thienyl	B1	152-154	898	921	592, 331, 257, 247, 219, 195, 145, 127, 113, 95 and 87.
4-Tetrahydropyranyl	A1	175-176	914	937	608, 333, 275, 249, 221, 197, 145, 127, 113, 95, and 87.
	A2	220 (dec)	932	955	351, 333, 275, 267, 249, 239, 221, 197, 145, 127, 113, 95 and 87.
	B1	177-183	900	923	594, 333, 249, 197, 145, 127, 113, 95 and 87.

25 Substituent (R ²)	Sub-class	m.p. °C.	Theoretical Mol. Wt.	(M+Na) ⁺ From FAB Mass Spec.	m/e for Principle Fragments in the EI Mass. Spec.
	B2	173-178	918	941	612, 351, 333, 267, 261, 249, 239, 221, 207, 197, 145, 127, 113, 95 and 87.
	H ₂ B1*	160-163	902	925	486, 335, 269, 261, 257, 251, 223, 199, 145, 127, 113, 95 and 87.
1-Methyl-3-methoxypropyl	B1	143-150	902	925	596, 335, 257, 251, 223, 199, 145, 127, 113, 95 and 87.
1-Methylbut-3-ynyl	B1	95-100	882	905	576, 466, 315, 261, 257, 231, 203, 179, 145, 127, 113, 95 and 87.
	B2	107-110	900	923	594, 466, 333, 315, 261, 257, 249, 231, 221, 203, 179, 145, 127, 113, 95 and 87.

25 Substituent (R ²)	Sub- class	m.p. °C.	Theoretical Mol. Wt.	(M+Na) ⁺ From FAB Mass Spec.	m/e for Principle Fragments in the EI Mass. Spec.
3-Cyclopentenyl	B1	150-152	882	905	576, 315, 261, 257, 248, 239, 231, 211, 203, 179, 145, 127, 113, 95 and 87.
3,4-Dihydro- pyran-2-yl	A1	130-135	912	935	331, 275, 257, 247, 219, 195, 145, 127, 113, 95 and 87.

* H₂B1 = dihydro B1 derivative. Prepared from corresponding B1 derivative by the procedure of Example 20.

EXAMPLE 19

25-Cyclobutyl-22,23-dihydro-avermectin B1

CL
L
P
H
The product of Example 11 in benzene is hydrogenated in the presence of tris(triphenylphosphine)rhodium (I) chloride according to the procedure of EP-A-0001689 to yield the corresponding compound of formula (I) wherein each of R and R¹ is H. The product of Example 12 is similarly converted to the corresponding dihydro derivative.

EXAMPLE 20

25-Cyclohexyl-22,23-dihydro-avermectin B1

CL
L
P
3
3
33
25
64
33 30
35
Dry benzene (200 ml) was purged first with a stream of nitrogen, then hydrogen. Tris(triphenylphosphine)rhodium (I) chloride (Wilkinson's catalyst) (665 mg) was then added. The passage of hydrogen was continued until the solution was yellow, and then for a further 10 minutes. 25-Cyclohexyl-avermectin B1 (2.010 g) was then added under a nitrogen blanket, and hydrogen bubbled through the solution for 24 hours. The solution was then evaporated to dryness. The residue was dissolved in methanol (50 ml) and evaporated; this was repeated. The residue was extracted with two portions of a 3:1 ether:hexane mixture (2 x 100 ml), and filtered. The combined filtrates were evaporated to dryness and chromatographed over silica gel (250 g of 230-900 mesh), eluting with an ether:methanol mixture (9:1). The relevant fractions were combined and evaporated to dryness to give crude product (2.25 g). This was purified using preparative HPLC, in three batches of 750 mg each, on a 42 mm x 30 cm Dynamax column, eluting initially with methanol:water (85:15), graduating to methanol:water (83:17) over 15 minutes, at a flow rate of 95 ml/min. Appropriate fractions were pooled and evaporated to give the title compound (1.43 g; 81%) as a white powder, m.p. 150° C. (dec.). (See Table 1 for additional characterizing data.)

EXAMPLE 21

13-Deoxy-25-cyclopentyl-avermectin A2-aglycone

CL
L
P
5 The product of Example 1 is treated with dilute
sulphuric acid at room temperature and the resulting
aglycone product is isolated and reacted with t-butyldi-
methysilylchloride in dimethylformamide to provide the
23-O-t-butyldimethysilyl aglycone derivative. This is
dissolved in methylene chloride containing 4-dimethyl-
aminopyridine and diisopropylethylamine, cooled in ice
10 and treated dropwise with 4-nitrobenzenesulphonylchloride
to yield the 13-chloro-13-deoxy product. This is finally
dehalogenated by reaction with tributyltinhydride and
deprotected with methanol containing a trace of para-
toluene sulphonic acid following the procedures described
15 in EP-A-0002615 to provide the compound of the formula I
wherein each of R, R¹ and R⁴ is H, R³ is OH, and R² is
cyclopentyl. In like manner, the compounds of Examples
14 7-10 and 13-20 are converted to the corresponding
13-deoxy derivatives.

CL
L
P
20 EXAMPLE 22

Drench Formulation

The product of any one of the preceding Examples
was dissolved in polyethylene glycol (average molecular
weight 300) to give a solution containing 400 micro-
25 grams/ml for use as a drench formulation.

CL
L
P
30 EXAMPLE 23

Anthelmintic Activity

I
Anthelmintic activity was evaluated against
Caenorhabditis elegans using the in vitro screening
30 test described by K. G. Simpkin and G. L. Coles in
Parasitology, 1979, 79, 19. The products of Examples 1,
7 and 9-16 all killed 100% of the worms at a well con-
centration of 0.1 micrograms per ml.

EXAMPLE 24

Insecticidal Activity

Activity against adult house fly Musca domestica is demonstrated using a standard test procedure in which flies are anaesthetised under carbon dioxide and 0.1 microlitres of acetone containing the test compound is deposited on the thorax of female flies. The product of Examples 1, 7 and 9-16 all killed 100% of the treated flies at a dose of 0.01 micrograms per fly.

CL

L

PI

5

14